Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to ...

Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

The European Commission (EC) has approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases.

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...